Home Careers Contact

Price: 4.05

Change: 0.00

Day High: 4.15
Day Low: 3.96
Volume: 980,462

4:00 PM ET | Mar 22, 2017
Delayed 20 min., by eSignal.



Shareholder Tools

Committee Composition

  Audit Nominating and Governance Compensation
Garheng Kong, M.D., Ph.D Chairman of the Board Member of Audit Committee   Committee Chair for Compensation Committee
David Zaccardelli, Pharm.D.      
Acting Chief Executive Officer

From 2004 until 2016, Dr. Zaccardelli served in several senior management roles at United Therapeutics, including chief operating officer, chief manufacturing officer and executive vice president, pharmaceutical development and operations. Prior to joining United Therapeutics, Dr. Zaccardelli founded and led a startup company focused on contract pharmaceutical development services, from 1997 through 2003. From 1988 to 1996, Dr. Zaccardelli worked at Burroughs Wellcome & Co. and Glaxo Wellcome, Inc. in a variety of clinical research positions. He also served as director of clinical and scientific affairs for Bausch & Lomb Pharmaceuticals from 1996 to 1997. Dr. Zaccardelli received his Doctor of Pharmacy degree from the University of Michigan.


Richard Kent, M.D.     Member of Compensation Committee
David Gill Committee Chair for Audit Committee    
Dov A. Goldstein, M.D., M.B.A.   Committee Chair for Nominating and Governance Committee  
John H. Johnson   Member of Nominating and Governance Committee  
P. Sherrill Neff     Member of Compensation Committee
Michael Dougherty Member of Audit Committee Member of Nominating and Governance Committee  
Chair of the Board = Chair of the Board Committee Chair = Chair of the Committee Committee Member = Member

Stock transaction information provided by EDGAR Online. Cempra, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.